SELZENTRY

Compare SELZENTRY  to:
Compare
Compare

Generic Name for SELZENTRY

Maraviroc 150mg, 300mg; tabs.

Legal Classification:

Rx

Pharmacological Class for SELZENTRY

CCR5 co-receptor antagonist.

Manufacturer of SELZENTRY

Pfizer Labs

Indications for SELZENTRY

HIV-1 infection in treatment-experienced adults infected with only CCR5-tropic HIV-1 detectable, who have evidence of viral replication and HIV-1 strains resistant to multiple antiretrovirals.

Adult dose for SELZENTRY

Swallow whole. ≥16yrs: Concomitant CYP3A inhibitors (eg, PIs except tipranavir/ritonavir, delavirdine, ketoconazole, itraconazole, clarithromycin, nefazodone, telithromycin) (with or without a CYP3A inducer): 150mg twice daily. Other concomitant drugs, including tipranavir/ritonavir, nevirapine, NRTIs, enfuvirtide: 300mg twice daily. Concomitant CYP3A inducers (eg, efavirenz, rifampin, carbamazepine, phenobarbital, phenytoin) (without a strong CYP3A inhibitor): 600mg twice daily. Renal dysfunction (CrCl<50mL/min) and CYP3A inhibitors: monitor closely for side effects (eg, dizziness).

Children's dosing for SELZENTRY

<16yrs: not recommended.

Precautions for SELZENTRY

Do tropism testing before starting therapy. Pre-existing liver dysfunction or co-infected with viral hepatitis B or C. Consider discontinuing therapy if hepatitis or elevated LFTs with rash or other systemic symptoms develop. Cardiovascular risk factors. Postural hypotension. Monitor for immune reconstitution syndrome, infections, malignancies. Pregnancy (Cat. B). Nursing mothers: not recommended.

Interactions for SELZENTRY

Concomitant St. John's wort: not recommended. May affect, or be affected by, CYP3A inhibitors or inducers and drugs affected by p-glycoprotein (eg, potentiated by ketoconazole, lopinavir/ritonavir, ritonavir, saquinavir, atazanavir; antagonized by rifampin, efavirenz). Caution with antihypertensives.

Adverse Reactions for SELZENTRY

Upper respiratory tract infections, cough, pyrexia, upper respiratory infections, rash, musculoskeletal symptoms, constipation, dizziness; hepatotoxicity (may be preceded by systemic allergic reaction; immediately evaluate if occurs); others (see literature).

How is SELZENTRY supplied?

Tabs—60

Related Disease:

HIV~antivirals

Related Resources

FDA reviews cardiac risk of Invirase in combination with Norvir

February 23, 2010

The FDA has notified healthcare professionals and patients that it is reviewing clinical trial data about a potentially serious effect on the heart associated with the use of Invirase (saquinavir, from Roche) in combination with Norvir (ritonavir, from Abbott).

Heat-stable Norvir tablets approved

February 16, 2010

The FDA has approved a heat-stable formulation of Norvir tablets (ritonavir, from Abbott) that can be stored at room temperature.

Videx and Videx EC labeling revised to include risk of non-cirrhotic portal hypertension

January 29, 2010

The FDA has notified healthcare professionals and patients that the use of Videx or Videx EC (didanosine, from Bristol-Myers Squibb) may cause non-cirrhotic portal hypertension, a rare but serious complication.

Prezista labeling updated to include 96-week data

January 28, 2010

Tibotec Therapeutics announced that the FDA has approved an updated label for Prezista (darunavir tablets) which includes 96-week data from the ARTEMIS and TITAN studies.

Exel/Exelint infusion set needles recalled

January 26, 2010

FDA notified healthcare professionals of a Class I recall of Exel/Exelint Huber needles, Exel/Exelint Huber Infusion Sets, and Exel/Exelint "Securetouch+" Safety Huber Infusion Sets due to 'coring,' the cutting or dislodging of silicone cores or slivers from the ports into which they are inserted).